Jeff Moehlenkamp, PhD
Dr. Moehlenkamp brings over 16 years of development experience with Bristol-Myers Squibb. He has a PhD in pharmacology and is a board certified toxicologist. He has extensive study director/monitor experience, led or supported multiple small and large molecule development programs within diverse therapeutic areas, demonstrated expertise in developing compounds in virology, performed nonclinical safety due diligence reviews, and played pivotal operational and managerial roles in both nonclinical toxicology study conduct and CRO oversight. At Aclairo, Jeff is a senior consultant who designs and support nonclinical safety programs including regulatory document preparation and design, monitor, and interpret GLP studies.